<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b1e7ffe5-7d5f-4e02-a9c9-3d9ad3fac23e"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for CLONIDINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS.<br/>
      <br/>CLONIDINE HYDROCHLORIDE extended-release tablets, for oral use<br/>Initial U.S. Approval: 1974</title>
   <effectiveTime value="20250307"/>
   <setId root="1b4fb182-8194-4fdd-bf9b-f7e60e734179"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="079947873" root="1.3.6.1.4.1.519.1"/>
            <name>Somerset Therapeutics, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="079947873" root="1.3.6.1.4.1.519.1"/>
                  <name>Somerset Therapeutics, LLC</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="449909329" root="1.3.6.1.4.1.519.1"/>
                        <name>Bluepharma – Industria Farmaceutica, S.A.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-044" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-044" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-044" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70069-044" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4c1b73de-85c7-4d55-a17a-1822b20a452d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250307"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70069-044" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Clonidine Hydrochloride</name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Clonidine Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="0.1" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="W76I6XXF06" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Clonidine Hydrochloride</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="MN3L5RMN02" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>clonidine</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>silicon dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>starch, corn</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium lauryl sulfate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70069-044-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250304"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211433" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE">
                              <originalText>off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="6" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">U;77</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="56118416-320d-4432-81bc-986d9d8104c2"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID2">Clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications <content styleCode="italics">[see <linkHtml href="#ID130">Clinical Studies (14)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID4">Clonidine hydrochloride is a centrally acting alpha<sub>2</sub>-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID5">
               <id root="281f1012-58d1-44e7-a082-f8250deb67b7"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID7" styleCode="Disc">
                           <item>Start with one 0.1 mg tablet at bedtime for one week. Increase daily dosage in increments of 0.1 mg/day at weekly intervals until the desired response is achieved. Take twice a day, with either an equal or higher split dosage being given at bedtime, as depicted below (<linkHtml href="#ID12">2.2</linkHtml>)</item>
                        </list>
                        <table ID="ID8" width="100%" styleCode="Noautorules">
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Total Daily Dose</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Morning Dose</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Bedtime Dose</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 0.1 mg/day<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 mg<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 0.2 mg/day<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 mg<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 0.3 mg/day<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.2 mg<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 0.4 mg/day<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.2 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.2 mg<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered" ID="ID9" styleCode="Disc">
                           <item>Do      not crush, chew or break tablet before swallowing. (<linkHtml href="#ID10">2.1</linkHtml>)</item>
                           <item>Do      not substitute for other clonidine products on a mg-per-mg basis, because      of differing pharmacokinetic profiles. (<linkHtml href="#ID10">2.1</linkHtml>)</item>
                           <item>When      discontinuing, taper the dose in decrements of no more than 0.1 mg every 3      to 7 days to avoid rebound hypertension. (<linkHtml href="#ID16">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID10">
                     <id root="7b9479fe-8401-48f1-bb9c-16a9a9f59fb0"/>
                     <title>2.1 General Dosing Information</title>
                     <text>
                        <paragraph ID="ID11">Clonidine hydrochloride is an extended-release tablet to be taken orally with or without food. <content styleCode="underline">Swallow tablets whole. Do not crush, chew, or break tablets because this will increase the rate of clonidine release.</content>
                        </paragraph>
                        <paragraph>Due to the lack of controlled clinical trial data and differing pharmacokinetic profiles, substitution of clonidine hydrochloride extended-release tablets for other clonidine products on a mg-per-mg basis is not recommended <content styleCode="italics">[see <linkHtml href="#ID114">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID12">
                     <id root="00f2522f-bf20-46dd-94e4-9ec562dfabde"/>
                     <title>2.2 Dose Selection</title>
                     <text>
                        <paragraph ID="ID13">The dose of clonidine hydrochloride extended-release tablets, administered either as monotherapy or as adjunctive therapy to a psychostimulant, should be individualized according to the therapeutic needs and response of the patient. Dosing should be initiated with one 0.1 mg tablet at bedtime, and the daily dosage should be adjusted in increments of 0.1 mg/day at weekly intervals until the desired response is achieved. Doses should be taken twice a day, with either an equal or higher split dosage being given at bedtime (see <linkHtml href="#ID14">Table 1</linkHtml>).</paragraph>
                        <table ID="ID14" width="100%" styleCode="Noautorules">
                           <caption>  Table 1 Clonidine Hydrochloride Extended-Release Tablets Dosing Guidance </caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center"> Total Daily Dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center"> Morning Dose<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center"> Bedtime Dose<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 0.1 mg/day<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 mg<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 0.2 mg/day<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 mg<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 0.3 mg/day<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.1 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.2 mg<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> 0.4 mg/day<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.2 mg<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.2 mg<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID15">Doses of clonidine hydrochloride higher than 0.4 mg/day (0.2 mg twice daily) were not evaluated in clinical trials for ADHD and are not recommended.</paragraph>
                        <paragraph>When clonidine hydrochloride extended-release tablets are being added-on to a psychostimulant, the dose of the psychostimulant can be adjusted depending on the patient's response to clonidine hydrochloride extended-release tablets.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID16">
                     <id root="8788d615-c01c-47cf-a680-f5ef9ee6ba71"/>
                     <title>2.3 Discontinuation</title>
                     <text>
                        <paragraph ID="ID17">When discontinuing clonidine hydrochloride extended-release tablets, the total daily dose should be tapered in decrements of no more than 0.1 mg every 3 to 7 days to avoid rebound hypertension <content styleCode="italics">[see <linkHtml href="#ID35">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID18">
                     <id root="e8becae3-1c1c-42d7-af0f-10455924c8ac"/>
                     <title>2.4 Missed Doses</title>
                     <text>
                        <paragraph ID="ID19">If patients miss a dose of clonidine hydrochloride extended-release tablets, they should skip that dose and take the next dose as scheduled. Do not take more than the prescribed total daily amount of clonidine hydrochloride extended-release tablets in any 24-hour period.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID20">
               <id root="a025cdae-e7aa-417f-a84f-d9424b21be34"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID21">Clonidine hydrochloride extended-release tablets are available in a 0.1 mg strength formulation. The 0.1 mg tablets are white to off-white round, biconvex tablets with debossing: "U" on one side and "77" on the other side. Clonidine hydrochloride extended-release tablets must be swallowed whole and never crushed, cut or chewed.</paragraph>
               </text>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID23">Extended-release tablets: 0.1 mg, not scored.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID24">
               <id root="3cbf7049-e318-45f1-9010-bb0e79130eb6"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID25">Clonidine hydrochloride extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to clonidine. Reactions have included generalized rash, urticaria, and angioedema <content styleCode="italics">[see <linkHtml href="#ID41">Adverse Reactions (6)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID27">History of a hypersensitivity reaction to clonidine. Reactions have included generalized rash, urticaria, angioedema.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID28">
               <id root="fd7edc3a-9b95-44f3-b9b9-01915bbfc5d5"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID30" styleCode="Disc">
                           <item>Hypotension/bradycardia/syncope:      Titrate slowly and monitor vital signs frequently in patients at risk for      hypotension, heart block, bradycardia, syncope, cardiovascular disease,      vascular disease, cerebrovascular disease or chronic renal failure.      Measure heart rate and blood pressure prior to initiation of therapy,      following dose increases, and periodically while on therapy. Avoid      concomitant use of drugs with additive effects unless clinically      indicated. Advise patients to avoid becoming dehydrated or overheated. (<linkHtml href="#ID31">5.1</linkHtml>)</item>
                           <item>Somnolence/Sedation:      Has been observed with clonidine hydrochloride extended-release tablets.      Consider the potential for additive sedative effects with CNS depressant      drugs. Caution patients against operating heavy equipment or driving until      they know how they respond to clonidine hydrochloride extended-release      tablets. (<linkHtml href="#ID33">5.2</linkHtml>)</item>
                           <item>Cardiac      Conduction Abnormalities: May worsen sinus node dysfunction and      atrioventricular (AV) block, especially in patients taking other      sympatholytic drugs. Titrate slowly and monitor vital signs frequently. (<linkHtml href="#ID39">5.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID31">
                     <id root="a7b68e40-8000-48a5-878e-34f3f31837f5"/>
                     <title>5.1 Hypotension/Bradycardia</title>
                     <text>
                        <paragraph ID="ID32">Treatment with clonidine hydrochloride extended-release tablets can cause dose-related decreases in blood pressure and heart rate <content styleCode="italics">[see <linkHtml href="#ID46">Adverse Reactions (6.1)</linkHtml>].</content> Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy. Titrate clonidine hydrochloride extended-release tablets slowly in patients with a history of hypotension, and those with underlying conditions that may be worsened by hypotension and bradycardia; e.g., heart block, bradycardia, cardiovascular disease, vascular disease, cerebrovascular disease, or chronic renal failure. In patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, advise patients to avoid becoming dehydrated or overheated. Monitor blood pressure and heart rate, and adjust dosages accordingly in patients treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID33">
                     <id root="23a72904-f321-4866-b50e-20af6f651f48"/>
                     <title>5.2 Sedation and Somnolence</title>
                     <text>
                        <paragraph ID="ID34">Somnolence and sedation were commonly reported adverse reactions in clinical studies. In patients that completed 5 weeks of therapy in a controlled, fixed dose pediatric monotherapy study, 31% of patients treated with 0.4 mg/day and 38% treated with 0.2 mg/day versus 4% of placebo treated patients reported somnolence as an adverse event. In patients that completed 5 weeks of therapy in a controlled flexible dose pediatric adjunctive to stimulants study, 19% of patients treated with clonidine hydrochloride+stimulant versus 7% treated with placebo+stimulant reported somnolence. Before using clonidine hydrochloride extended-release tablets with other centrally active depressants (such as phenothiazines, barbiturates, or benzodiazepines), consider the potential for additive sedative effects. Caution patients against operating heavy equipment or driving until they know how they respond to treatment with clonidine hydrochloride extended-release tablets. Advise patients to avoid use with alcohol.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID35">
                     <id root="5c25787d-33e4-46fa-8ab9-05012ce324c3"/>
                     <title>5.3 Rebound Hypertension</title>
                     <text>
                        <paragraph ID="ID36">Abrupt discontinuation of clonidine hydrochloride extended-release tablets can cause rebound hypertension. In adults with hypertension, sudden cessation of clonidine hydrochloride extended-release formulation treatment in the 0.2 to 0.6 mg/day range resulted in reports of headache, tachycardia, nausea, flushing, warm feeling, brief lightheadedness, tightness in chest, and anxiety. In adults with hypertension, sudden cessation of treatment with immediate-release clonidine has, in some cases, resulted in symptoms such as nervousness, agitation, headache, and tremor accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma.</paragraph>
                        <paragraph>No studies evaluating abrupt discontinuation of clonidine hydrochloride in children with ADHD have been conducted; however, to minimize the risk of rebound hypertension, gradually reduce the dose of clonidine hydrochloride extended-release tablets in decrements of no more than 0.1 mg every 3 to 7 days. Patients should be instructed not to discontinue clonidine hydrochloride extended-release tablets therapy without consulting their physician due to the potential risk of withdrawal effects.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID37">
                     <id root="94d09603-7542-4a41-9efe-7605337e60bf"/>
                     <title>5.4 Allergic Reactions</title>
                     <text>
                        <paragraph ID="ID38">In patients who have developed localized contact sensitization to clonidine transdermal system, continuation of clonidine transdermal system or substitution of oral clonidine hydrochloride extended-release tablets therapy may be associated with the development of a generalized skin rash.</paragraph>
                        <paragraph>In patients who develop an allergic reaction from clonidine transdermal system, substitution of oral clonidine hydrochloride extended-release tablets may also elicit an allergic reaction (including generalized rash, urticaria, or angioedema).</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID39">
                     <id root="584ff7f4-3d77-454f-a9f3-68f234b5da56"/>
                     <title>5.5 Cardiac Conduction Abnormalities</title>
                     <text>
                        <paragraph ID="ID40">The sympatholytic action of clonidine may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. There have been post-marketing reports of patients with conduction abnormalities and/or taking other sympatholytic drugs who developed severe bradycardia requiring IV atropine, IV isoproterenol, and temporary cardiac pacing while taking clonidine. Titrate clonidine hydrochloride extended-release tablets slowly and monitor vital signs frequently in patients with cardiac conduction abnormalities or patients concomitantly treated with other sympatholytic drugs.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID41">
               <id root="7d5aba12-0e89-4d46-ab87-5f0615c14ae5"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID42">The following serious adverse reactions are described in greater detail elsewhere in labeling:</paragraph>
                  <list listType="unordered" ID="ID43" styleCode="Disc">
                     <item>Hypotension/bradycardia <content styleCode="italics">[see <linkHtml href="#ID31">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Sedation      and somnolence <content styleCode="italics">[see <linkHtml href="#ID33">Warnings and Precautions      (5.2)</linkHtml>]</content>
                     </item>
                     <item>Rebound      hypertension <content styleCode="italics">[see <linkHtml href="#ID35">Warnings and Precautions      (5.3)</linkHtml>]</content>
                     </item>
                     <item>Allergic      reactions <content styleCode="italics">[see <linkHtml href="#ID37">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Cardiac      Conduction Abnormalities <content styleCode="italics">[see <linkHtml href="#ID39">Warnings and Precautions      (5.5)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID45">Most common adverse reactions (incidence at least 5% and twice the rate of placebo) as monotherapy in ADHD: somnolence, fatigue, irritability, nightmare, insomnia, constipation, dry mouth. (6.1)</paragraph>
                        <paragraph>Most common adverse reactions (incidence at least 5% and twice the rate of placebo) as adjunct therapy to psychostimulant in ADHD: somnolence, fatigue, decreased appetite, dizziness. (6.1)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics LLC, at 1- 800-417-9175, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID46">
                     <id root="ffc4cbe8-d035-4520-af43-53f9f71c4333"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph ID="ID47">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Two clonidine hydrochloride ADHD clinical studies (Study 1, CLON-301 and Study 2, CLON-302) evaluated 256 patients in two 8-week placebo-controlled studies.</paragraph>
                        <paragraph>A third clonidine hydrochloride ADHD clinical study (Study 3, SHN-KAP-401) evaluated 135 children and adolescents in a 40-week placebo-controlled randomized-withdrawal study.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                     <component>
                        <section ID="ID48">
                           <id root="052f95e9-b183-4f97-8279-f19a80d843f4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID49">
                                 <content styleCode="bold">
                                    <content styleCode="underline">Study 1: Fixed-dose Clonidine Hydrochloride Extended-Release Tablets Monotherapy</content>
                                 </content>
                              </paragraph>
                              <paragraph>Study 1 (CLON-301) was a short-term, multi-center, randomized, double-blind, placebo-controlled study of two fixed doses (0.2 mg/day or 0.4 mg/day) of clonidine hydrochloride in children and adolescents (6 to 17 years of age) who met DSM-IV criteria for ADHD hyperactive or combined inattentive/hyperactive subtypes.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Most Common Adverse Reactions </content>(incidence of ≥ 5% and at least twice the rate of placebo): somnolence, fatigue, irritability, insomnia, nightmare, constipation, dry mouth.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Adverse Events Leading to Discontinuation of Clonidine Hydrochloride </content>– Five patients (7%) in the low dose group (0.2 mg), 15 patients (20%) in the high dose group (0.4 mg), and 1 patient in the placebo group (1%) reported adverse reactions that led to discontinuation. The most common adverse reactions that led to discontinuation were somnolence and fatigue.</paragraph>
                              <paragraph>Commonly observed adverse reactions (incidence of ≥2% in either active treatment group and greater than the rate on placebo) during the treatment period are listed in Table 2.</paragraph>
                              <table ID="ID50" width="100%" styleCode="Noautorules">
                                 <caption>  Table 2 Common Adverse Reactions in the Fixed-Dose Monotherapy Trial – Treatment Period (Study 1) </caption>
                                 <col width="25%"/>
                                 <col width="25%"/>
                                 <col width="25%"/>
                                 <col width="25%"/>
                                 <tbody>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                       <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                          <content styleCode="bold"> Percentage of Patients Reporting Event</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="bottom" styleCode="Lrule Botrule Rrule" align="left">
                                          <content styleCode="bold"> Preferred Term</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> Clonidine Hydrochloride</content>
                                          <br/>
                                          <content styleCode="bold"> 0.2 mg/day</content>
                                          <br/>
                                          <content styleCode="bold"> N=76</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> Clonidine Hydrochloride</content>
                                          <br/>
                                          <content styleCode="bold"> 0.4 mg/day</content>
                                          <br/>
                                          <content styleCode="bold"> N=78</content>
                                          <br/>
                                       </td>
                                       <td styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> Placebo</content>
                                          <br/>
                                          <content styleCode="bold"> (N=76)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> PSYCHIATRIC DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Somnolence<footnote ID="ID50_0">Somnolence includes the terms "somnolence" and "sedation".</footnote>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 38%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 31%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 4%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Nightmare<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 4%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 9%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Emotional Disorder<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 4%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 4%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 1%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Aggression<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 1%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Tearfulness<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 1%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Enuresis<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 0%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 4%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Sleep Terror<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 0%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Poor Quality Sleep<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> NERVOUS SYSTEM DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Headache<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 20%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 13%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 16%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Insomnia<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 5%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 6%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 1%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Tremor<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 1%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 4%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Abnormal Sleep-Related Event<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> GASTROINTESTINAL DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Upper Abdominal Pain<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 15%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 10%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 12%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Nausea<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 4%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 5%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 3%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Constipation<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 1%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 6%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Dry Mouth<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> GENERAL DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Fatigue<footnote ID="ID50_1">Fatigue includes the terms "fatigue" and "lethargy".</footnote>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 16%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 13%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 1%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Irritability<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 9%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> CARDIAC DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Dizziness<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 7%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 5%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Bradycardia<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> INVESTIGATIONS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Increased Heart Rate<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> METABOLISM AND NUTRITION DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Decreased Appetite<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph ID="ID51">Commonly observed adverse reactions (incidence of ≥ 2% in either active treatment group and greater than the rate on placebo) during the taper period are listed in Table 3.</paragraph>
                              <table ID="ID52" width="100%" styleCode="Noautorules">
                                 <caption>  Table 3 Common Adverse Reactions in the Fixed-Dose Monotherapy Trial – Taper Period<footnote ID="ID52_0">Taper Period: 0.2 mg dose, week 8; 0.4 mg dose, weeks 6 to 8; Placebo dose, weeks 6 to 8</footnote> (Study 1) </caption>
                                 <col width="25%"/>
                                 <col width="25%"/>
                                 <col width="25%"/>
                                 <col width="25%"/>
                                 <tbody>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                       <td colspan="3" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                          <content styleCode="bold"> Percentage of Patients Reporting Event</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="bottom" styleCode=" Lrule Rrule" align="left">
                                          <content styleCode="bold"> Preferred Term</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center">
                                          <content styleCode="bold"> Clonidine Hydrochloride</content>
                                          <br/>
                                          <content styleCode="bold"> 0.2 mg/day</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center">
                                          <content styleCode="bold"> Clonidine Hydrochloride</content>
                                          <br/>
                                          <content styleCode="bold"> 0.4 mg/day</content>
                                          <br/>
                                       </td>
                                       <td rowspan="2" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> Placebo</content>
                                          <br/>
                                          <content styleCode="bold"> (N=76)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> N=76</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> N=78</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Abdominal Pain Upper<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Headache<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Gastrointestinal Viral<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Somnolence<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Heart Rate Increased<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Otitis Media Acute<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID53">
                           <id root="a9ae600f-4fd1-4f80-b29f-db09f756b43f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID54">
                                 <content styleCode="bold">
                                    <content styleCode="underline">Study 2: Flexible-dose Clonidine Hydrochloride Extended-Release Tablets as Adjunctive Therapy to Psychostimulants</content>
                                 </content>
                              </paragraph>
                              <paragraph>Study 2 (CLON-302) was a short-term, randomized, double-blind, placebo-controlled study of a flexible dose of clonidine hydrochloride as adjunctive therapy to a psychostimulant in children and adolescents (6 to 17 years) who met DSM-IV criteria for ADHD hyperactive or combined inattentive/hyperactive subtypes during which clonidine hydrochloride was initiated at 0.1 mg/day and titrated up to 0.4 mg/day over a 3-week period. Most clonidine hydrochloride treated patients (75.5%) were escalated to the maximum dose of 0.4 mg/day.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Most Common Adverse Reactions </content>(incidence of ≥5% and at least twice the rate of placebo): somnolence, fatigue, decreased appetite, dizziness.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Adverse Events Leading to Discontinuation </content>– There was one patient in the CLON+STM group (1%) who discontinued because of an adverse event (severe bradyphrenia, with severe fatigue).</paragraph>
                              <paragraph>Commonly observed adverse reactions (incidence of ≥2% in the treatment group and greater than the rate on placebo) during the treatment period are listed in Table 4.</paragraph>
                              <table ID="ID55" width="100%" styleCode="Noautorules">
                                 <caption>  Table 4 Common Adverse Reactions in the Flexible-Dose Adjunctive to Stimulant Therapy Trial – Treatment Period (Study 2) </caption>
                                 <col width="33%"/>
                                 <col width="33%"/>
                                 <col width="33%"/>
                                 <tbody>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Toprule Rrule"/>
                                       <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                          <content styleCode="bold"> Percentage of Patients Reporting Event</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Botrule Rrule" align="left">
                                          <content styleCode="bold"> Preferred Term</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> Clonidine Hydrochloride+STM</content>
                                          <br/>
                                          <content styleCode="bold"> (N=102)</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                          <content styleCode="bold"> PBO+STM</content>
                                          <br/>
                                          <content styleCode="bold"> (N=96)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> PSYCHIATRIC DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Somnolence<footnote ID="ID55_0">Somnolence includes the terms: "somnolence" and "sedation".</footnote>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 19%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 7%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Aggression<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 2%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 1%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Affect Lability<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 2%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 1%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Emotional Disorder<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> GENERAL DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Fatigue<footnote ID="ID55_1">Fatigue includes the terms "fatigue" and "lethargy".</footnote>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 14%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 4%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Irritability<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> NERVOUS SYSTEM DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> Headache<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 7%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule" align="center"> 12%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Insomnia<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> GASTROINTESTINAL DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Upper Abdominal Pain<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 7%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> RESPIRATORY DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nasal Congestion<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> METABOLISM AND NUTRITION DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Decreased Appetite<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 6%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode=" Lrule Rrule" align="left"> CARDIAC DISORDERS<br/>
                                       </td>
                                       <td valign="top" styleCode=" Rrule"/>
                                       <td valign="top" styleCode=" Rrule"/>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Dizziness<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 5%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph ID="ID56">Commonly observed adverse reactions (incidence of ≥2% in the treatment group and greater than the rate on placebo) during the taper period are listed in Table 5.</paragraph>
                              <table ID="ID57" width="100%" styleCode="Noautorules">
                                 <caption>  Table 5 Common Adverse Reactions in the Flexible-Dose Adjunctive to Stimulant Therapy Trial – Taper Period<footnote ID="ID57_0">Taper Period: weeks 6 to 8</footnote> (Study 2) </caption>
                                 <col width="33%"/>
                                 <col width="33%"/>
                                 <col width="33%"/>
                                 <tbody>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Toprule Rrule" align="left">
                                          <br/>
                                       </td>
                                       <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                          <content styleCode="bold"> Percentage of Patients Reporting Event</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Botrule Rrule" align="left">
                                          <content styleCode="bold"> Preferred Term</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> Clonidine</content>
                                          <br/>
                                          <content styleCode="bold"> Hydrochloride+STM</content>
                                          <br/>
                                          <content styleCode="bold"> (N=102)</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                          <content styleCode="bold"> PBO+STM</content>
                                          <br/>
                                          <content styleCode="bold"> (N=96)</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nasal Congestion<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 4%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Headache<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Irritability<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Throat Pain<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 1%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Gastroenteritis Viral<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Rash<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2%<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0%<br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID58">
                           <id root="79f8d6f8-a778-404e-93e4-89cfbf6f19c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID59">
                                 <content styleCode="bold">
                                    <content styleCode="underline">Adverse Reactions Leading to Discontinuation</content>
                                 </content>
                              </paragraph>
                              <paragraph>Thirteen percent (13%) of patients receiving clonidine hydrochloride discontinued from the pediatric monotherapy study due to adverse events, compared to 1% in the placebo group. The most common adverse reactions leading to discontinuation of clonidine hydrochloride monotherapy treated patients were from somnolence/sedation (5%) and fatigue (4%).</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID60">
                           <id root="2758501a-17d3-4e56-8fdd-9acf51315353"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID61">
                                 <content styleCode="bold">
                                    <content styleCode="underline">Effect on Blood Pressure and Heart Rate</content>
                                 </content>
                              </paragraph>
                              <paragraph>In patients that completed 5 weeks of treatment in a controlled, fixed-dose monotherapy study in pediatric patients, during the treatment period the maximum placebo-subtracted mean change in systolic blood pressure was -4.0 mmHg on clonidine hydrochloride 0.2 mg/day and -8.8 mmHg on clonidine hydrochloride 0.4 mg/day. The maximum placebo-subtracted mean change in diastolic blood pressure was -4.0 mmHg on clonidine hydrochloride 0.2 mg/day and -7.3 mmHg on clonidine hydrochloride 0.4 mg/day. The maximum placebo-subtracted mean change in heart rate was -4.0 beats per minute on clonidine hydrochloride 0.2 mg/day and -7.7 beats per minute on clonidine hydrochloride 0.4 mg/day.</paragraph>
                              <paragraph>During the taper period of the fixed-dose monotherapy study the maximum placebo-subtracted mean change in systolic blood pressure was +3.4 mmHg on clonidine hydrochloride 0.2 mg/day and -5.6 mmHg on clonidine hydrochloride 0.4 mg/day. The maximum placebo-subtracted mean change in diastolic blood pressure was +3.3 mmHg on clonidine hydrochloride 0.2 mg/day and -5.4 mmHg on clonidine hydrochloride 0.4 mg/day. The maximum placebo-subtracted mean change in heart rate was -0.6 beats per minute on clonidine hydrochloride 0.2 mg/day and -3.0 beats per minute on clonidine hydrochloride 0.4 mg/day.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID62">
                     <id root="aa0fa36c-d24f-4646-bb62-702635c73009"/>
                     <title>6.2 Post-marketing Experience</title>
                     <text>
                        <paragraph ID="ID63">The following adverse reactions have been identified during post-approval use of clonidine hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events exclude those already mentioned in 6.1:</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Psychiatric: </content>
                           </content>hallucinations</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Cardiovascular: </content>
                           </content>Q-T prolongation</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID64">
               <id root="571fec13-42b7-43fb-bf44-cdcc2e139e0a"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="ID65">The following have been reported with other oral immediate release formulations of clonidine:</paragraph>
                  <table ID="ID66" width="100%" styleCode="Noautorules">
                     <caption>  Table 6 Clinically Important Drug Interactions </caption>
                     <col width="33%"/>
                     <col width="33%"/>
                     <col width="33%"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Concomitant Drug Name or Drug Class</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Clinical Rationale</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Clinical Recommendation</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Tricyclic antidepressants<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Increase blood pressure and may counteract clonidine's hypotensive effects<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Monitor blood pressure and adjust as needed<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Antihypertensive drugs<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Potentiate clonidine's hypotensive effects<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Monitor blood pressure and adjust as needed<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> CNS depressants<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Potentiate sedating effects<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Avoid use<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Drugs that affect sinus node function or AV node conduction (e.g., digitalis, calcium channel blockers, beta blockers)<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Potentiate bradycardia and risk of AV block<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Avoid use<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID68" styleCode="Disc">
                           <item>Sedating      Drugs: Clonidine may potentiate the CNS-depressive effects of alcohol,      barbiturates or other sedating drugs. (<linkHtml href="#ID64">7</linkHtml>)</item>
                           <item>Tricyclic      Antidepressants: May reduce the hypotensive effect of clonidine. (<linkHtml href="#ID64">7</linkHtml>)</item>
                           <item>Drugs      Known to Affect Sinus Node Function or AV Nodal Conduction: Caution is      warranted in patients receiving clonidine concomitantly with agents known      to affect sinus node function or AV nodal conduction (e.g., digitalis,      calcium channel blockers and beta-blockers) due to a potential for additive      effects such as bradycardia and AV block. (<linkHtml href="#ID64">7</linkHtml>)</item>
                           <item>Antihypertensive      drugs: Use caution when coadministered with clonidine hydrochloride      extended-release tablets. (<linkHtml href="#ID64">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID69">
               <id root="e7ccaf9f-ab6f-468c-bef6-ed1341454a6f"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID71" styleCode="Disc">
                           <item>Renal Impairment: The dosage of clonidine hydrochloride extended-release tablets must be adjusted according to the degree of impairment, and patients should be carefully monitored. (<linkHtml href="#ID93">8.6</linkHtml>, <linkHtml href="#ID114">12.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID72">
                     <id root="f1970e66-9590-4050-bffe-2aeb33407486"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250307"/>
                     <component>
                        <section ID="ID73">
                           <id root="c5f8f9cc-b48f-4e1c-b9ff-17b935102d8c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID74">Pregnancy Exposure Registry</paragraph>
                              <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including clonidine hydrochloride, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visiting https://womensmentalhealth.org/adhd-medications/.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID75">
                           <id root="48d07062-5484-480b-8b3a-69027496c72f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID76">
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Prolonged experience with clonidine in pregnant women over several decades, based on published literature, including controlled trials, a retrospective cohort study and case reports, have not identified a drug associated risk of major birth defects, miscarriage, and adverse maternal or fetal outcomes. In animal embryofetal studies, increased resorptions were seen in rats and mice administered oral clonidine hydrochloride from implantation through organogenesis at 10 and 5 times, respectively, the maximum recommended human dose (MRHD) given to adolescents on a mg/m<sup>2</sup> basis. No developmental effects were seen in rabbits administered oral clonidine hydrochloride during organogenesis at doses up to 3 times the MRHD <content styleCode="italics">(see <linkHtml href="#ID78">Data</linkHtml>)</content>. </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID77">
                           <id root="49362faa-828b-4c2b-9ab2-23c8d65b316b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID78">
                                 <content styleCode="underline">Data </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                           <component>
                              <section ID="ID79">
                                 <id root="3e38af0c-6623-41c5-937d-c2a3e56a45b9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph ID="ID80">
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Oral administration of clonidine hydrochloride to pregnant rabbits during the period of embryo/fetal organogenesis at doses of up to 80 mcg/kg/day (approximately 3 times the oral maximum recommended daily dose [MRHD] of 0.4 mg/day given to adolescents on a mg/m<sup>2</sup> basis) produced no developmental effects. In pregnant rats, however, doses as low as 15 mcg/kg/day (1/3 the MRHD given to adolescents on a mg/m<sup>2</sup> basis) were associated with increased resorptions in a study in which dams were treated continuously from 2 months prior to mating and throughout gestation. Increased resorptions were not associated with treatment at the same or at higher dose levels (up to 3 times the MRHD) when treatment of the dams was restricted to gestation days 6 to 15. Increases in resorptions were observed in both rats and mice at 500 mcg/kg/day (10 and 5 times the MRHD in rats and mice, respectively) or higher when the animals were treated on gestation days 1 to 14; 500 mcg/kg/day was the lowest dose employed in this study.</paragraph>
                                 </text>
                                 <effectiveTime value="20250307"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID81">
                     <id root="f19f05d9-3068-4a04-b097-890e5a76f2c3"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250307"/>
                     <component>
                        <section ID="ID82">
                           <id root="9db1dbe8-b0d1-4d99-bfcc-f5b8e63c9f88"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID83">
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on published lactation studies, clonidine hydrochloride is present in human milk at relative infant doses ranging from 4.1% to 8.4% of the maternal weight-adjusted dosage. Although in most cases, there were no reported adverse effects in breastfed infants exposed to clonidine, there is one case report of sedation, hypotonia, and apnea in an infant exposed to clonidine through breast milk. If an infant is exposed to clonidine hydrochloride through breastmilk, monitor for symptoms of hypotension and bradycardia, such as sedation, lethargy, tachypnea and poor feeding <content styleCode="italics">(see <linkHtml href="#ID81">Clinical Considerations</linkHtml>).</content> The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clonidine hydrochloride and any potential adverse effects on the breastfed child from clonidine hydrochloride or from the underlying maternal condition. Exercise caution when clonidine hydrochloride is administered to a nursing woman.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID84">
                           <id root="e602cb53-1c20-4343-a3bd-17acf94af08c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID85">
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Monitor breastfeeding infants exposed to clonidine hydrochloride through breast milk for symptoms of hypotension and/or bradycardia such as sedation, lethargy, tachypnea, and poor feeding.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID86">
                     <id root="d4264c97-7154-45f1-98f4-7826d0298c81"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20250307"/>
                     <component>
                        <section ID="ID87">
                           <id root="6d659f69-4675-4b5a-a3b8-c4346d527cfa"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID88">
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                              <paragraph>Based on findings in Animal studies revealed that clonidine hydrochloride may impair fertility in females and males of reproductive potential <content styleCode="italics">[see <linkHtml href="#ID123">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID89">
                     <id root="60a8e823-eeee-4835-bb67-affb957d7da2"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID90">The safety and efficacy of clonidine hydrochloride in the treatment of ADHD have been established in pediatric patients 6 to 17 years of age. Use of clonidine hydrochloride in pediatric patients 6 to 17 years of age is supported by three adequate and well-controlled studies; a short-term, placebo-controlled monotherapy trial, a short-term adjunctive therapy trial and a longer-term randomized monotherapy trial <content styleCode="italics">[see <linkHtml href="#ID130">Clinical Studies (14)</linkHtml>].</content> Safety and efficacy in pediatric patients below the age of 6 years has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                     <component>
                        <section ID="ID91">
                           <id root="67eb47f0-aff0-4375-8911-c51e2eb1cd7a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID92">
                                 <content styleCode="underline">Juvenile Animal Data</content>
                              </paragraph>
                              <paragraph>In studies in juvenile rats, clonidine hydrochloride alone or in combination with methylphenidate had an effect on bone growth at clinically relevant doses and produced a slight delay in sexual maturation in males at 3 times the maximum recommended human dose (MRHD) for clonidine and methylphenidate.</paragraph>
                              <paragraph>In a study where juvenile rats were treated orally with clonidine hydrochloride from day 21 of age to adulthood, a slight delay in onset of preputial separation (delayed sexual maturation) was seen in males treated with 300 mcg/kg/day, which is approximately 3 times the MRHD of 0.4 mg/day on a mg/m<sup>2</sup> basis. The no-effect dose was 100 mcg/kg/day, which is approximately equal to the MRHD. There was no drug effects on fertility or on other measures of sexual or neurobehavioral development.</paragraph>
                              <paragraph>In a study where juvenile rats were treated with clonidine alone (300 mcg/kg/day) or in combination with methylphenidate (10 mg/kg/day in females and 50/30 mg/kg/day in males; the dose was lowered from 50 to 30 mg/kg/day in males due to self-injurious behavior during the first week of treatment) from day 21 of age to adulthood, decreases in bone mineral density and mineral content were observed in males treated with 300 mcg/kg/day clonidine alone and in combination with 50/30 mg/kg/day methylphenidate and a decrease in femur length was observed in males treated with the combination at the end of the treatment period. These doses are approximately 3 times the MRHD of 0.4 mg/day clonidine and 54 mg/day methylphenidate on a mg/m<sup>2</sup> basis. All these effects in males were not reversed at the end of a 4-week recovery period. In addition, similar findings were seen in males treated with a lower dose of clonidine (30 mcg/kg/day) in combination with 50 mg/kg/day of methylphenidate and a decrease in femur length was observed in females treated with clonidine alone at the end of the recovery period. These effects were accompanied by a decrease in body weight gain in treated animals during the treatment period but the effect was reversed at the end of the recovery period. A delay in preputial separation (sexual maturation) was observed in males treated with the combination treatment of 300 mcg/kg/day clonidine and 50/30 mg/kg/day methylphenidate. There was no effect on reproduction or sperm analysis in these males.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID93">
                     <id root="0c0a435c-3204-4ec2-9e56-334800279d50"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID94">The impact of renal impairment on the pharmacokinetics of clonidine in children has not been assessed. The initial dosage of clonidine hydrochloride extended-release tablets should be based on degree of impairment. Monitor patients carefully for hypotension and bradycardia, and titrate to higher doses cautiously. Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine hydrochloride extended-release tablets following dialysis.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID95">
               <id root="dfa25a7a-616f-4ee8-931a-7acb0b75d2a7"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20250307"/>
               <component>
                  <section ID="ID96">
                     <id root="d386e1bf-9aca-45ee-b53c-87466e319c0e"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph ID="ID97">Clonidine hydrochloride is not a controlled substance and has no known potential for abuse or dependence.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID98">
               <id root="d23ff886-ffc9-4a0a-8112-a23ff55b856c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20250307"/>
               <component>
                  <section ID="ID99">
                     <id root="66503aae-1ef2-4dd1-9ae0-9428ca89c138"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID100">
                           <content styleCode="bold">
                              <content styleCode="underline">Symptoms</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                     <component>
                        <section ID="ID101">
                           <id root="cace710d-20a8-4ff3-852f-d6bfae219c00"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID102">
                                 <content styleCode="bold">Clonidine overdose: </content>hypertension may develop early and may be followed by hypotension, bradycardia, respiratory depression, hypothermia, drowsiness, decreased or absent reflexes, weakness, irritability and miosis. The frequency of CNS depression may be higher in children than adults. Large overdoses may result in reversible cardiac conduction defects or dysrhythmias, apnea, coma and seizures. Signs and symptoms of overdose generally occur within 30 minutes to two hours after exposure.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID103">
                     <id root="34af3bff-6777-4ef2-9ac3-190c542bb0f3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID104">
                           <content styleCode="bold">
                              <content styleCode="underline">Treatment</content>
                           </content>
                        </paragraph>
                        <paragraph>Consult with a Certified Poison Control Center (1-800-222-1222) for up-to-date guidance and advice.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID105">
               <id root="da60cb6d-815c-4f5f-ad24-fe7818298615"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID106">Clonidine hydrochloride extended-release tablets are a centrally acting alpha<sub>2</sub>-adrenergic agonist available as 0.1 mg extended-release tablets for oral administration. Each 0.1 mg tablet is equivalent to 0.087 mg of the free base.</paragraph>
                  <paragraph>The inactive ingredients are sodium lauryl sulfate, lactose monohydrate, hypromellose, pregelatinized starch, colloidal silicon dioxide, and magnesium stearate. The formulation is designed to delay the absorption of active drug in order to decrease peak to trough plasma concentration differences. Clonidine hydrochloride is an imidazoline derivative and exists as a mesomeric compound. The chemical name is 2-(2,6 dichlorophenylamino)-2-imidazoline hydrochloride. The following is the structural formula:</paragraph>
                  <paragraph>C<sub>9</sub>H<sub>9</sub>Cl<sub>2</sub>N<sub>3</sub>∙HCl<renderMultiMedia referencedObject="IMGID1061"/>Mol. Wt. 266.56</paragraph>
                  <paragraph ID="ID108">Clonidine hydrochloride, USP is an odorless, bitter, white, crystalline substance soluble in water and alcohol.</paragraph>
               </text>
               <effectiveTime value="20250307"/>
               <component>
                  <observationMedia ID="IMGID1061">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="b1e7ffe5-7d5f-4e02-a9c9-3d9ad3fac23e-106-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID109">
               <id root="de5480d6-4202-423f-8767-590f9439b9da"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250307"/>
               <component>
                  <section ID="ID110">
                     <id root="126129d3-9eb3-40f6-98ae-60e8a9ae3964"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID111">Clonidine stimulates alpha<sub>2</sub>-adrenergic receptors in the brain. Clonidine is not a central nervous system stimulant. The mechanism of action of clonidine in ADHD is not known.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID112">
                     <id root="45bfff78-d587-45eb-ae7d-2ed7a5af91a9"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID113">Clonidine is a known antihypertensive agent. By stimulating alpha<sub>2</sub>-adrenergic receptors in the brain stem, clonidine reduces sympathetic outflow from the central nervous system and decreases peripheral resistance, renal vascular resistance, heart rate, and blood pressure.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID114">
                     <id root="20b60f85-c134-486a-8fd0-5ea219560aee"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250307"/>
                     <component>
                        <section ID="ID115">
                           <id root="05b4b744-2024-4bf0-a63f-64c380f09972"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID116">
                                 <content styleCode="bold">
                                    <content styleCode="underline">Single-dose Pharmacokinetics in Adults</content>
                                 </content>
                              </paragraph>
                              <paragraph>Immediate-release clonidine hydrochloride and clonidine hydrochloride extended-release have different pharmacokinetic characteristics; dose substitution on a milligram for milligram basis will result in differences in exposure. A comparison across studies suggests that the C<sub>max</sub> is 50% lower for clonidine hydrochloride extended-release compared to immediate-release clonidine hydrochloride.</paragraph>
                              <paragraph>Following oral administration of an immediate release formulation, plasma clonidine concentration peaks in approximately 3 to 5 hours and the plasma half-life ranges from 12 to 16 hours. The half-life increases up to 41 hours in patients with severe impairment of renal function. Following oral administration about 40% to 60% of the absorbed dose is recovered in the urine as unchanged drug in 24 hours.</paragraph>
                              <paragraph>About 50% of the absorbed dose is metabolized in the liver. Although studies of the effect of renal impairment and studies of clonidine excretion have not been performed with clonidine hydrochloride extended-release, results are likely to be similar to those of the immediate release formulation.</paragraph>
                              <paragraph>The pharmacokinetic profile of clonidine hydrochloride extended-release administration was evaluated in an open-label, three-period, randomized, crossover study of 15 healthy adult subjects who received three single-dose regimens of clonidine: 0.1 mg of clonidine hydrochloride extended-release under fasted conditions, 0.1 mg of clonidine hydrochloride extended-release following a high fat meal, and 0.1 mg of clonidine immediate-release (Catapres<sup>®</sup>) under fasted conditions. Treatments were separated by one-week washout periods.</paragraph>
                              <paragraph>Mean concentration-time data from the 3 treatments are shown in Table 7 and Figure 1. After administration of clonidine hydrochloride extended-release, maximum clonidine concentrations were approximately 50% of the Catapres maximum concentrations and occurred approximately 5 hours later relative to Catapres. Similar elimination half-lives were observed and total systemic bioavailability following clonidine hydrochloride extended-release was approximately 89% of that following Catapres.</paragraph>
                              <paragraph>Food had no effect on plasma concentrations, bioavailability, or elimination half-life.</paragraph>
                              <table ID="ID117" width="100%" styleCode="Noautorules">
                                 <caption>  Table 7 Pharmacokinetic Parameters of Clonidine in Healthy Adult Volunteers </caption>
                                 <col width="14%"/>
                                 <col width="14%"/>
                                 <col width="14%"/>
                                 <col width="14%"/>
                                 <col width="14%"/>
                                 <col width="14%"/>
                                 <col width="14%"/>
                                 <tbody>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                          <br/>
                                       </td>
                                       <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                          <content styleCode="bold"> CATAPRES-Fasted</content>
                                          <br/>
                                          <content styleCode="bold"> n=15</content>
                                          <br/>
                                       </td>
                                       <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                          <content styleCode="bold"> Clonidine Hydrochloride Extended-Release-Fed</content>
                                          <br/>
                                          <content styleCode="bold"> n=15</content>
                                          <br/>
                                       </td>
                                       <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                          <content styleCode="bold"> Clonidine Hydrochloride Extended-Release-Fasted</content>
                                          <br/>
                                          <content styleCode="bold"> n=14</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                                          <content styleCode="bold"> Parameter</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> Mean</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> SD</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> Mean</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> SD</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> Mean</content>
                                          <br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center">
                                          <content styleCode="bold"> SD</content>
                                          <br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> C<sub>max</sub> (pg/mL)<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 443<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 59.6<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 235<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 34.7<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 258<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 33.3<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> AUC<sub>inf</sub> (hr*pg/mL)<br/>
                                       </td>
                                       <td styleCode=" Botrule Rrule" align="center"> 7313<br/>
                                       </td>
                                       <td styleCode=" Botrule Rrule" align="center"> 1812<br/>
                                       </td>
                                       <td styleCode=" Botrule Rrule" align="center"> 6505<br/>
                                       </td>
                                       <td styleCode=" Botrule Rrule" align="center"> 1728<br/>
                                       </td>
                                       <td styleCode=" Botrule Rrule" align="center"> 6729<br/>
                                       </td>
                                       <td styleCode=" Botrule Rrule" align="center"> 1650<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> hT<sub>max</sub> (hr)<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 2.07<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 0.5<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 6.80<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3.61<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 6.50<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 1.23<br/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> T<sub>1/2</sub> (hr)<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 12.57<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3.11<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 12.67<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3.76<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 12.65<br/>
                                       </td>
                                       <td valign="top" styleCode=" Botrule Rrule" align="center"> 3.56<br/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph ID="ID118">
                                 <content styleCode="bold">Figure 1 Mean Clonidine Concentration-Time Profiles after Single Dose Administration</content>
                              </paragraph>
                              <renderMultiMedia referencedObject="MM1"/>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID120">
                           <id root="8472c526-fb2d-4c54-9482-ad1f1617a467"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID121">
                                 <content styleCode="bold">
                                    <content styleCode="underline">Multiple-dose Pharmacokinetics in Children and Adolescents</content>
                                 </content>
                              </paragraph>
                              <paragraph>Plasma clonidine concentrations in children and adolescents (0.1 mg bid and 0.2 mg bid) with ADHD are greater than those of adults with hypertension with children and adolescents receiving higher doses on a mg/kg basis. Body weight normalized clearance (CL/F) in children and adolescents was higher than CL/F observed in adults with hypertension. Clonidine concentrations in plasma increased with increases in dose over the dose range of 0.2 to 0.4 mg/day. Clonidine CL/F was independent of dose administered over the 0.2 to 0.4 mg/day dose range. Clonidine CL/F appeared to decrease slightly with increases in age over the range of 6 to 17 years, and females had a 23% lower CL/F than males. The incidence of "sedation-like" AEs (somnolence and fatigue) appeared to be independent of clonidine dose or concentration within the studied dose range in the titration study. Results from the add-on study showed that clonidine CL/F was 11% higher in patients who were receiving methylphenidate and 44% lower in those receiving amphetamine compared to subjects not on adjunctive therapy.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="b1e7ffe5-7d5f-4e02-a9c9-3d9ad3fac23e-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID122">
               <id root="60bb7d31-d0b3-4c94-8567-9c37819dfb27"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250307"/>
               <component>
                  <section ID="ID123">
                     <id root="3948646e-b2b9-433e-ae8c-f2ffd4ce8d54"/>
                     <title>13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility</title>
                     <effectiveTime value="20250307"/>
                     <component>
                        <section ID="ID124">
                           <id root="7c4b4952-7c00-4804-ac17-bee1d9a2465d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID125">
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Clonidine hydrochloride was not carcinogenic when administered in the diet of rats (for up to 132 weeks) or mice (for up to 78 weeks) at doses of up to 1620 (male rats), 2040 (female rats), or 2500 (mice) mcg/kg/day. These doses are approximately 20, 25, and 15 times, respectively, the maximum recommended human dose (MRHD) of 0.4 mg/day on a mg/m<sup>2</sup> basis.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID126">
                           <id root="ba2982ef-d861-43c6-9edf-6c9f5e26ed08"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID127">
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>There was no evidence of genotoxicity in the Ames test for mutagenicity or mouse micronucleus test for clastogenicity.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID128">
                           <id root="079764db-0143-4754-ab4a-2b42bb81de87"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="ID129">
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>In a reproduction study, fertility of female rats appeared to be adversely affected at dose levels of 500 and 2000 mcg/kg/day (10 and 40 times the MRHD on a mg/ m<sup>2</sup> basis). Lower doses have not been adequately evaluated and a no adverse effect level could not be established.</paragraph>
                           </text>
                           <effectiveTime value="20250307"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID130">
               <id root="acae3212-92d2-4d93-b7bd-7c7e690953c2"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID131">Efficacy of clonidine hydrochloride in the treatment of ADHD was established in children and adolescents (6 to 17 years) in:</paragraph>
                  <list listType="unordered" ID="ID132" styleCode="Disc">
                     <item>One      short-term, placebo-controlled monotherapy trial (Study 1)</item>
                     <item>One      short-term adjunctive therapy to psychostimulants trial (Study 2)</item>
                     <item>One      randomized withdrawal trial as monotherapy (Study 3)</item>
                  </list>
               </text>
               <effectiveTime value="20250307"/>
               <component>
                  <section ID="ID133">
                     <id root="ba63cd82-1c60-4486-9044-8e06ee515519"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID134">
                           <content styleCode="bold">Short-term Monotherapy and Adjunctive Therapy to Psychostimulant Studies for ADHD</content>
                        </paragraph>
                        <paragraph>The efficacy of clonidine hydrochloride in the treatment of ADHD was established in 2 (one monotherapy and one adjunctive therapy) placebo-controlled trials in pediatric patients aged 6 to 17, who met DSM-IV criteria of ADHD hyperactive or combined hyperactive/inattentive subtypes. Signs and symptoms of ADHD were evaluated using the investigator administered and scored ADHD Rating Scale-IV-Parent Version (ADHDRS-IV) total score including hyperactive/impulsivity and inattentive subscales.</paragraph>
                        <paragraph>Study 1 (CLON-301), was an 8-week randomized, double-blind, placebo-controlled, fixed dose study of children and adolescents aged 6 to 17 (N=236) with a 5-week primary efficacy endpoint. Patients were randomly assigned to one of the following three treatment groups: clonidine hydrochloride (CLON) 0.2 mg/day (N=78), clonidine hydrochloride 0.4 mg/day (N=80), or placebo (N=78). Dosing for the clonidine hydrochloride groups started at 0.1 mg/day and was titrated in increments of 0.1 mg/week to their respective dose (as divided doses). Patients were maintained at their dose for a minimum of 2 weeks before being gradually tapered down to 0.1 mg/day at the last week of treatment. At both doses, improvements in ADHD symptoms were statistically significantly superior in clonidine hydrochloride-treated patients compared with placebo-treated patients at the end of 5 weeks as measured by the ADHDRS-IV total score (Table 8).</paragraph>
                        <paragraph>Study 2 (CLON-302) was an 8-week randomized, double-blind, placebo-controlled, flexible dose study in children and adolescents aged 6 to 17 (N=198) with a 5-week primary efficacy end point. Patients had been treated with a psychostimulant (methylphenidate or amphetamine) for four weeks with inadequate response. Patients were randomly assigned to one of two treatment groups: clonidine hydrochloride adjunct to a psychostimulant (N=102) or psychostimulant alone (N=96). The clonidine hydrochloride dose was initiated at 0.1 mg/day and doses were titrated in increments of 0.1 mg/week up to 0.4 mg/day, as divided doses, over a 3-week period based on tolerability and clinical response. The dose was maintained for a minimum of 2 weeks before being gradually tapered to 0.1 mg/day at the last week of treatment. ADHD symptoms were statistically significantly improved in clonidine hydrochloride plus stimulant group compared with the stimulant alone group at the end of 5 weeks as measured by the ADHDRS-IV total score (Table 8).</paragraph>
                        <table ID="ID135" width="100%" styleCode="Noautorules">
                           <caption>  Table 8 Short-Term Trials </caption>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="5">
                                    <paragraph styleCode="Footnote">SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule" align="left">
                                    <content styleCode="bold"> Study Number</content>
                                    <br/>
                                 </td>
                                 <td rowspan="2" valign="top" styleCode=" Toprule Botrule" align="left">
                                    <content styleCode="bold"> Treatment Group</content>
                                    <br/>
                                 </td>
                                 <td colspan="3" valign="top" styleCode=" Toprule Botrule" align="left">
                                    <content styleCode="bold"> Primary Efficacy Measure: ADHDRS-IV Total Score</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule" align="center">
                                    <content styleCode="bold"> Mean Baseline Score (SD)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule" align="center">
                                    <content styleCode="bold"> LS Mean Change from Baseline (SE)</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule" align="left">
                                    <content styleCode="bold"> Placebo-subtracted Difference</content>
                                    <footnote ID="ID135_0">Difference (drug minus placebo) in least-squares mean change from baseline.</footnote>
                                    <content styleCode="bold">  (95% CI)</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" align="left"> Study 1<br/>
                                 </td>
                                 <td valign="top" align="left"> Clonidine HCl (0.2 mg/day)<br/>
                                 </td>
                                 <td valign="top" align="left"> 43.8 (7.47)<br/>
                                 </td>
                                 <td valign="top" align="left"> -15.0 (1.38)<br/>
                                 </td>
                                 <td valign="top" align="left"> -8.5 (-12.2, -4.8)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td valign="top" align="left"> Clonidine HCl (0.4 mg/day)<br/>
                                 </td>
                                 <td valign="top" align="left"> 44.6 (7.73)<br/>
                                 </td>
                                 <td valign="top" align="left"> -15.6 (1.33)<br/>
                                 </td>
                                 <td valign="top" align="left"> -9.1 (-12.8, -5.5)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule" align="left"> Placebo<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="left"> 45.0 (8.53)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="left"> -6.5 (1.35)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="left"> --<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" align="left"> Study 2<br/>
                                 </td>
                                 <td valign="top" align="left"> Clonidine HCl (0.4 mg/day) + Psychostimulant<br/>
                                 </td>
                                 <td align="left"> 38.9 (6.95)<br/>
                                 </td>
                                 <td align="left"> -15.8 (1.18)<br/>
                                 </td>
                                 <td align="left"> -4.5 (-7.8, -1.1)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule"/>
                                 <td valign="top" styleCode=" Botrule" align="left"> Psychostimulant alone<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="left"> 39.0 (7.68)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="left"> -11.3 (1.24)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule" align="left"> --<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID136">
                     <id root="9394de4d-9dbc-4c98-b33e-4d9268557675"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID137">
                           <content styleCode="bold">Maintenance Monotherapy for ADHD</content>
                        </paragraph>
                        <paragraph>Study 3 was a double-blind, placebo-controlled, randomized-withdrawal study in children and adolescents aged 6 to 17 years (n=253) with DSM-IV-TR diagnosis of ADHD. The study consisted of a 10-week, open-label phase (4 weeks of dose optimization and 6 weeks of dose maintenance), a 26-week double-blind phase, and a 4-week taper-down and follow-up phase. All patients were initiated at 0.1 mg/day and increased at weekly intervals in increments of 0.1 mg/day until reaching personalized optimal dose (0.1, 0.2, 0.3 or 0.4 mg/day, as divided doses). Eligible patients had to demonstrate treatment response as defined by ≥ 30% reduction in ADHD-RS-IV total score and a Clinical Global Impression-Improvement score of 1 or 2 during the open label phase. Patients who sustained treatment response (n=135) until the end of the open label phase were randomly assigned to one of the two treatment groups, clonidine hydrochloride (N=68) and Placebo (N=67), to evaluate the long-term efficacy of maintenance dose of clonidine hydrochloride in the double-blind phase. The primary efficacy endpoint was the percentage of patients with treatment failure defined as a ≥ 30% increase (worsening) in ADHD-RS-IV total score and ≥ 2 points increase (worsening) in Clinical Global Impression – Severity Scale in 2 consecutive visits or early termination for any reason. A total of 73 patients experienced treatment failure in the double-blind phase: 31 patients (45.6%) in the clonidine hydrochloride group and 42 patients (62.7%) in the placebo group, with a statistically significant difference in the primary endpoint favoring clonidine hydrochloride extended-release tablets (Table 9). The cumulative proportion of patients with treatment failure over time during the double-blind phase is displayed in Figure 2.</paragraph>
                        <table ID="ID138" width="100%" styleCode="Noautorules">
                           <caption>  Table 9 Treatment Failure: Double-Blind Full Analysis Set (Study 3) </caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">ADHD-RS-IV = Attention Deficit Hyperactivity Disorder-Rating Scale-4<sup>th</sup> edition; CGI-S = Clinical Global Impression-Severity</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <sup>a</sup>At the same 2 consecutive visits a (1) 30% or greater reduction in ADHD-RS-IV, and (2) 2-point or more increase in CGI-S.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <sup>b</sup>Two subjects (1 placebo and 1 clonidine hydrochloride) withdrew consent, but met the clinical criteria for treatment failure.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3">
                                    <paragraph styleCode="Footnote">
                                       <sup>c</sup>Three subjects (all placebo) discontinued the study due to treatment failure, but met only the criterion for ADHD-RS-IV.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Study 3</content>
                                    <br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Double-Blind Full Analysis Set</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center">
                                    <content styleCode="bold"> Clonidine Hydrochloride</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Placebo</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Number of subjects<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 68<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 67<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Number of treatment failures<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 31 (45.6%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 42 (62.7%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" valign="top" styleCode="Lrule Botrule Rrule" align="left"> Basis of Treatment Failure<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Clinical criteria<sup>a ,b</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 11 (16.2%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 9 (13.4%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Lack of efficacy<sup>c</sup>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 1 (1.5%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 (4.5%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Withdrawal of informed assent/consent<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4 (5.9%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 20 (29.9%)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Other early terminations<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 15 (22.1%)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 10 (14.9%)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID139">
                           <content styleCode="bold">Figure 2: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Treatment Failure (Study 3)</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="b1e7ffe5-7d5f-4e02-a9c9-3d9ad3fac23e-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID141">
               <id root="3656ea6c-578f-42e8-8ec7-9b62ae72896f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID142">Clonidine hydrochloride extended-release tablet 0.1 mg is a white to off-white round, biconvex tablets with debossing: "U" on one side and "77" on the other side and supplied as follows.</paragraph>
                  <paragraph>Bottles of 60 tablets with child-resistant closure, NDC 70069-044-01 </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].</paragraph>
                  <paragraph>Dispense in a tight container as defined in the USP.</paragraph>
                  <paragraph>Keep clonidine hydrochloride extended-release tablets and all medicines out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20250307"/>
            </section>
         </component>
         <component>
            <section ID="ID145">
               <id root="33054bc0-a31f-4749-ae85-ca2a5282bf0f"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID146">Advise the patient to read the FDA-approved Patient Labeling (Patient Information)</paragraph>
               </text>
               <effectiveTime value="20250307"/>
               <component>
                  <section ID="ID147">
                     <id root="9fc72713-564d-4536-bb5c-c3ec8d9247d2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID148">
                           <content styleCode="bold">Dosage and Administration</content>
                        </paragraph>
                        <paragraph>Advise patients that clonidine hydrochloride extended-release tablets must be swallowed whole, never crushed, cut, or chewed, and may be taken with or without food. When initiating treatment, provide dosage escalation instructions <content styleCode="italics">[see <linkHtml href="#ID10">Dosage and Administration (2.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID149">
                     <id root="cd3ab7a9-bd7b-4450-9383-aed3a8a74bab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID150">
                           <content styleCode="bold">Missed Dose</content>
                        </paragraph>
                        <paragraph>If patients miss a dose of clonidine hydrochloride extended-release tablets, advise them to skip the dose and take the next dose as scheduled and not to take more than the prescribed total daily amount of clonidine hydrochloride extended-release tablets in any 24-hour period <content styleCode="italics">[see <linkHtml href="#ID18">Dosage and Administration (2.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID151">
                     <id root="79618033-34f2-46e3-adeb-53d7ef1b9a09"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID152">
                           <content styleCode="bold">Hypotension/Bradycardia</content>
                        </paragraph>
                        <paragraph>Advise patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, to avoid becoming dehydrated or overheated <content styleCode="italics">[see <linkHtml href="#ID31">Warnings and Precautions (5.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID153">
                     <id root="9a7a3e1c-8a9b-4b45-b34f-4860896f6d17"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID154">
                           <content styleCode="bold">Sedation and Somnolence</content>
                        </paragraph>
                        <paragraph>Instruct patients to use caution when driving a car or operating hazardous machinery until they know how they will respond to treatment with clonidine hydrochloride extended-release tablets. Also advise patients to avoid the use of clonidine hydrochloride extended-release tablets with other centrally active depressants and with alcohol <content styleCode="italics">[see <linkHtml href="#ID33">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID155">
                     <id root="47f81491-793b-4203-b2f6-1469d111b326"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID156">
                           <content styleCode="bold">Rebound Hypertension</content>
                        </paragraph>
                        <paragraph>Advise patients not to discontinue clonidine hydrochloride extended-release tablets abruptly <content styleCode="italics">[see <linkHtml href="#ID35">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID157">
                     <id root="e0d13ead-3634-439d-a768-995474b39877"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID158">
                           <content styleCode="bold">Allergic Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients to discontinue clonidine hydrochloride extended-release tablets and seek immediate medical attention if any signs or symptoms of a hypersensitivity reaction occur, such as generalized rash, urticaria, or angioedema <content styleCode="italics">[see <linkHtml href="#ID37">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID159">
                     <id root="6f60b59a-5dbb-4ef0-9eba-550004b4ef14"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID160">
                           <content styleCode="bold">Pregnancy Registry</content>
                        </paragraph>
                        <paragraph>Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in patients exposed to clonidine hydrochloride during pregnancy <content styleCode="italics">[see <linkHtml href="#ID72">Use in Specific Populations (8.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID161">
                     <id root="40779100-f114-461c-abbc-e538ccd67177"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID162">
                           <content styleCode="bold">Lactation</content>
                        </paragraph>
                        <paragraph>Advise breastfeeding women using clonidine hydrochloride to monitor infants for excess sedation, decreased muscle tone, and respiratory depression and to seek medical care if they notice these signs <content styleCode="italics">[see <linkHtml href="#ID81">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="ID163">
                     <id root="017ed0c5-6ac2-477e-86e0-385005a20e77"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID164">
                           <content styleCode="bold">Fertility</content>
                        </paragraph>
                        <paragraph>Advise females and males of reproductive potential that clonidine hydrochloride may impair fertility <content styleCode="italics">[see <linkHtml href="#ID86">Use in Specific Populations (8.3) </linkHtml>
                              <linkHtml href="#ID123">and Nonclinical Toxicology (13.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID165">
               <id root="0906c983-618b-4f7d-8471-46bd6faa1ad2"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph ID="ID166">Manufactured for:</paragraph>
                  <paragraph>Somerset Therapeutics, LLC</paragraph>
                  <paragraph>Somerset, NJ 08873</paragraph>
                  <paragraph>Made in Portugal</paragraph>
                  <paragraph>All trademarks are property of their respective owners.</paragraph>
                  <paragraph>Revised: 10/2024</paragraph>
               </text>
               <effectiveTime value="20250307"/>
            </section>
         </component>
         <component>
            <section ID="ID167">
               <id root="07e469f1-4bc4-418d-883b-6fc172fd6d15"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <paragraph ID="ID168">
                     <content styleCode="bold">Patient Information  Clonidine Hydrochloride (kloe' ni deen hye'' droe klor' ide)   Extended-Release Tablets</content>
                  </paragraph>
                  <paragraph>Read the Patient Information that comes with clonidine hydrochloride extended-release tablets before you start taking it and each time you get a refill. There may be new information. This Patient Information leaflet does not take the place of talking to your doctor about your medical condition or treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are clonidine hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Clonidine hydrochloride extended-release tablets are a prescription medicine used for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Your doctor may prescribe clonidine hydrochloride extended-release tablets alone or together with certain other ADHD medicines.</paragraph>
                  <list listType="unordered" ID="ID169" styleCode="Disc">
                     <item>Clonidine      hydrochloride extended-release tablets are not a central nervous system      (CNS) stimulant.</item>
                     <item>Clonidine      hydrochloride extended-release tablets should be used as part of a total      treatment program for ADHD that may include counseling or other therapies.</item>
                  </list>
                  <paragraph ID="ID170">
                     <content styleCode="bold">Who should not take clonidine hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID171" styleCode="Disc">
                     <item>Do not take clonidine hydrochloride extended-release tablets if you are allergic to clonidine in clonidine hydrochloride extended-release tablets. See the end of this leaflet for a complete list of ingredients in clonidine hydrochloride extended-release tablets.</item>
                  </list>
                  <paragraph ID="ID172">
                     <content styleCode="bold">What should I tell my doctor before taking clonidine hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>Before you take clonidine hydrochloride extended-release tablets, tell your doctor if you:</paragraph>
                  <list listType="unordered" ID="ID173" styleCode="Disc">
                     <item>have      kidney problems</item>
                     <item>have      low or high blood pressure</item>
                     <item>have      a history of passing out (syncope)</item>
                     <item>have      heart problems, including history of heart attack</item>
                     <item>have      had a stroke or have stroke symptoms</item>
                     <item>had      a skin reaction (such as a rash) after taking clonidine in a transdermal      form (skin patch)</item>
                     <item>have      any other medical conditions</item>
                     <item>are      pregnant or plan to become pregnant. It is not known if clonidine      hydrochloride extended-release tablets will harm your unborn baby. Talk to      your doctor if you are pregnant or plan to become pregnant.<list listType="ordered" styleCode="LittleRoman">
                           <item>There      is a pregnancy registry for females who are exposed to ADHD medications,      including clonidine hydrochloride extended-release tablets, during      pregnancy. The purpose of the registry is to collect information about the      health of females exposed to clonidine hydrochloride extended-release      tablets and their baby. If you or your child becomes pregnant during      treatment with clonidine hydrochloride extended-release tablets, talk to      your healthcare provider about registering with the National Pregnancy      Registry of ADHD Medications at 1-866-961-2388 or visit online at      https://womensmentalhealth.org/adhdmedications/.</item>
                        </list>
                     </item>
                     <item>are      breastfeeding or plan to breastfeed. Clonidine hydrochloride      extended-release tablets can pass into your breast milk. Talk to your      doctor about the best way to feed your baby if you take clonidine      hydrochloride extended-release tablets.</item>
                  </list>
                  <paragraph ID="ID174">Tell your doctor about all of the medicines that you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.</paragraph>
                  <paragraph>Clonidine hydrochloride extended-release tablets and certain other medicines may affect each other causing serious side effects. Sometimes the doses of other medicines may need to be changed while taking clonidine hydrochloride extended-release tablets.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Especially tell your doctor if you take:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID175" styleCode="Disc">
                     <item>anti-depression      medicines</item>
                     <item>heart      or blood pressure medicine</item>
                     <item>other      medicines that contain clonidine</item>
                     <item>a      medicine that makes you sleepy (sedation)</item>
                  </list>
                  <paragraph ID="ID176">Ask your doctor or pharmacist for a list of these medicines, if you are not sure if your medicine is listed above.</paragraph>
                  <paragraph>Know the medicines that you take. Keep a list of your medicines with you to show your doctor and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take clonidine hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID177" styleCode="Disc">
                     <item>Take      clonidine hydrochloride extended-release tablets exactly as your doctor      tells you to take it.</item>
                     <item>Your      doctor will tell you how many clonidine hydrochloride extended-release      tablets to take and when to take them. Your doctor may change your dose of      clonidine hydrochloride extended-release tablets. Do not change your dose      of clonidine hydrochloride extended-release tablets without talking to      your doctor.</item>
                     <item>Do      not stop taking clonidine hydrochloride extended-release tablets without      talking to your doctor.</item>
                     <item>Clonidine      hydrochloride extended-release tablets can be taken with or without food.</item>
                     <item>Clonidine      hydrochloride extended-release tablets should be taken 2 times a day (in      the morning and at bedtime).</item>
                     <item>If      you miss a dose of clonidine hydrochloride extended-release tablets, skip      the missed dose. Just take the next dose at your regular time. Do not take      two doses at the same time.</item>
                     <item>Take      clonidine hydrochloride extended-release tablets whole. Do not chew, crush      or break clonidine hydrochloride extended-release tablets. Tell your      doctor if you cannot swallow clonidine hydrochloride extended-release      tablets whole. You may need a different medicine.</item>
                     <item>If      you take too much clonidine hydrochloride extended-release tablets, call      your Poison Control Center or go to the nearest hospital emergency room      right away.</item>
                  </list>
                  <paragraph ID="ID178">
                     <content styleCode="bold">What should I avoid while taking clonidine hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID179" styleCode="Disc">
                     <item>Do      not drink alcohol or take other medicines that make you sleepy or dizzy      while taking clonidine hydrochloride extended-release tablets until you      talk with your doctor. Clonidine hydrochloride extended-release tablets      taken with alcohol or medicines that cause sleepiness or dizziness may      make your sleepiness or dizziness worse.</item>
                     <item>Do      not drive, operate heavy machinery or do other dangerous activities until      you know how clonidine hydrochloride extended-release tablets will affect      you.</item>
                     <item>Avoid      becoming dehydrated or overheated.</item>
                  </list>
                  <paragraph ID="ID180">
                     <content styleCode="bold">What are possible side effects of clonidine hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Clonidine hydrochloride extended-release tablets may cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered" ID="ID181" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Low      blood pressure and low heart rate. </content>Your      doctor should check your heart rate and blood pressure before starting      treatment and regularly during treatment with clonidine hydrochloride      extended-release tablets.</item>
                     <item>Sleepiness.</item>
                     <item>Withdrawal      symptoms. Suddenly stopping clonidine hydrochloride extended-release      tablets may cause withdrawal symptoms including: increased blood pressure,      headache, increased heart rate, lightheadedness, tightness in your chest      and nervousness.</item>
                  </list>
                  <paragraph ID="ID182">The most common side effects of clonidine hydrochloride extended-release tablets include:</paragraph>
                  <list listType="unordered" ID="ID183" styleCode="Disc">
                     <item>sleepiness</item>
                     <item>tiredness</item>
                     <item>irritability</item>
                     <item>trouble      sleeping (insomnia)</item>
                     <item>nightmare</item>
                     <item>constipation</item>
                     <item>dry      mouth</item>
                     <item>decreased      appetite</item>
                     <item>dizziness</item>
                  </list>
                  <paragraph ID="ID184">Tell your doctor if you have any side effects that bother you or that does not go away.</paragraph>
                  <paragraph>These are not all of the possible side effects of clonidine hydrochloride extended-release tablets. For more information, ask your doctor or pharmacist.</paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store clonidine hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID185" styleCode="Disc">
                     <item>Store      clonidine hydrochloride extended-release tablets between 68° to 77°F      (20° to 25°C).</item>
                     <item>Keep      clonidine hydrochloride extended-release tablets in a tightly closed      container.</item>
                     <item>Clonidine      hydrochloride extended-release tablets come in a child-resistant package.</item>
                  </list>
                  <paragraph ID="ID186">
                     <content styleCode="bold">Keep clonidine hydrochloride extended-release tablets and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of clonidine hydrochloride extended-release tablets</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use clonidine hydrochloride extended-release tablets for a condition for which it was not prescribed.</paragraph>
                  <paragraph>Do not give clonidine hydrochloride extended-release tablets to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                  <paragraph>This Patient Information leaflet summarizes the most important information about clonidine hydrochloride extended-release tablets. If you would like more information, talk with your doctor. You can also ask your doctor or pharmacist for information about clonidine hydrochloride extended-release tablets that is written for healthcare professionals.</paragraph>
                  <paragraph>For more information about clonidine hydrochloride extended-release tablets contact Somerset Therapeutics, LLC at 1-800-417-9175.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in clonidine hydrochloride extended-release tablets?</content>
                  </paragraph>
                  <list listType="unordered" ID="ID193" styleCode="Disc">
                     <item>Active Ingredient: clonidine hydrochloride</item>
                     <item>Inactive Ingredients: sodium lauryl sulfate, lactose monohydrate, hypromellose, pregelatinized starch, colloidal silicon dioxide, and magnesium stearate</item>
                  </list>
                  <paragraph ID="ID188">Manufactured for:</paragraph>
                  <paragraph>Somerset Therapeutics, LLC</paragraph>
                  <paragraph>Somerset, NJ 08873</paragraph>
                  <paragraph>Made in Portugal</paragraph>
                  <paragraph>Revised: 10/2024</paragraph>
               </text>
               <effectiveTime value="20250307"/>
            </section>
         </component>
         <component>
            <section ID="ID189">
               <id root="5caa830f-bf13-4878-acb4-b64c30d5e4f3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.1 mg Tablet Bottle Label</title>
               <text>
                  <paragraph ID="ID190">
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>NDC 70069-044-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Clonidine Hydrochloride</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Extended-Release</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">0.1 mg</content>
                  </paragraph>
                  <paragraph>60 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250307"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Desc</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="b1e7ffe5-7d5f-4e02-a9c9-3d9ad3fac23e-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>